Patient Demographics and Baseline Characteristics
| Characteristics . | Tacrolimus N = 165 (%) . | Cyclosporine N = 164 (%) . | P Value . |
|---|---|---|---|
| Age | |||
| Median (range) | 40.0 (17-61) | 40.0 (16-63) | 1.0* |
| 12-19 | 3 (2) | 10 (6) | 0.26-151 |
| 20-29 | 34 (20) | 25 (15) | |
| 30-39 | 44 (27) | 46 (28) | |
| 40-49 | 56 (34) | 57 (35) | |
| ≥50 | 28 (17) | 26 (16) | |
| Sex | 0.39-151 | ||
| Male | 93 (56) | 100 (61) | |
| Female | 72 (44) | 64 (39) | |
| Race | 0.25-151 | ||
| White | 146 (89) | 135 (82) | |
| African-American | 7 (4) | 13 (8) | |
| Others | 12 (7) | 16 (10) | |
| Karnofsky score | |||
| Median (range) | 80 (20-100) | 80 (20-100) | 0.89* |
| CMV serology (donor/ recipient) | 0.18-151 | ||
| Negative/negative | 38 (23) | 30 (19) | |
| Negative/positive | 35 (21) | 25 (15) | |
| Positive/negative | 22 (13) | 20 (12) | |
| Positive/positive | 69 (42) | 89 (54) | |
| Unknown | 1 (1) | 0 (0) | |
| Stage of malignancy | 0.02-151 | ||
| Advanced | 68 (41) | 48 (29) | |
| Nonadvanced | 97 (59) | 116 (71) | |
| Diagnosis | 0.70-152 | ||
| Myelodysplasia | 7 (4) | 13 (8) | |
| Acute lymphoid leukemia | 18 (11) | 14 (9) | |
| Acute myeloid leukemia | 45 (27) | 44 (27) | |
| Chronic myeloid leukemia | 51 (31) | 57 (35) | |
| Non-Hodgkin's lymphoma | 13 (8) | 16 (10) | |
| Hodgkin's disease | 2 (1) | 2 (1) | |
| Myeloma | 14 (9) | 9 (5) | |
| Chronic lymphoid leukemia | 6 (4) | 4 (2) | |
| Others | 9 (5) | 5 (3) |
| Characteristics . | Tacrolimus N = 165 (%) . | Cyclosporine N = 164 (%) . | P Value . |
|---|---|---|---|
| Age | |||
| Median (range) | 40.0 (17-61) | 40.0 (16-63) | 1.0* |
| 12-19 | 3 (2) | 10 (6) | 0.26-151 |
| 20-29 | 34 (20) | 25 (15) | |
| 30-39 | 44 (27) | 46 (28) | |
| 40-49 | 56 (34) | 57 (35) | |
| ≥50 | 28 (17) | 26 (16) | |
| Sex | 0.39-151 | ||
| Male | 93 (56) | 100 (61) | |
| Female | 72 (44) | 64 (39) | |
| Race | 0.25-151 | ||
| White | 146 (89) | 135 (82) | |
| African-American | 7 (4) | 13 (8) | |
| Others | 12 (7) | 16 (10) | |
| Karnofsky score | |||
| Median (range) | 80 (20-100) | 80 (20-100) | 0.89* |
| CMV serology (donor/ recipient) | 0.18-151 | ||
| Negative/negative | 38 (23) | 30 (19) | |
| Negative/positive | 35 (21) | 25 (15) | |
| Positive/negative | 22 (13) | 20 (12) | |
| Positive/positive | 69 (42) | 89 (54) | |
| Unknown | 1 (1) | 0 (0) | |
| Stage of malignancy | 0.02-151 | ||
| Advanced | 68 (41) | 48 (29) | |
| Nonadvanced | 97 (59) | 116 (71) | |
| Diagnosis | 0.70-152 | ||
| Myelodysplasia | 7 (4) | 13 (8) | |
| Acute lymphoid leukemia | 18 (11) | 14 (9) | |
| Acute myeloid leukemia | 45 (27) | 44 (27) | |
| Chronic myeloid leukemia | 51 (31) | 57 (35) | |
| Non-Hodgkin's lymphoma | 13 (8) | 16 (10) | |
| Hodgkin's disease | 2 (1) | 2 (1) | |
| Myeloma | 14 (9) | 9 (5) | |
| Chronic lymphoid leukemia | 6 (4) | 4 (2) | |
| Others | 9 (5) | 5 (3) |